1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

Regulatory News In Brief

FDA issues safety notice on Covidien catheter. Medtronic stent graft selected for FDA’s early feasibility pilot program. More regulatory news.

FDA issued a safety communication June 28 warning physicians and patients about the risk of catheter entrapment with the Onyx liquid embolic system, manufactured by Covidien’s ev3 unit. The liquid material is used to block blood flow in abnormally formed brain vessels, known as brain arteriovenous malformations. A catheter is used to deliver the Onyx liquid to the vessels. Since Jan. 1, 2005, FDA has learned of more than 100 cases, including nine deaths, of catheter breakage that may be related to catheter entrapment. In 54 cases, the catheter could not be removed, so part of the catheter and the implanted Onyx material remained in the patient. The most serious complications include hemorrhage and death. FDA notes that neither Onyx nor the catheter is meant to be a long-term implant. FDA approved updated labeling for the product in April to convey risks related to the catheter entrapment.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Medtech Seeks Inclusion In EU’s Groundbreaking Life Sciences Strategy

 
• By Amanda Maxwell

As the EU Life Sciences Strategy aims to drive innovation, the medtech sector is pushing for a pivotal role in a mission intended to embrace green and digital transitions, address regulatory obstacles and reduce dependency on external sources.

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 
• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

Update: Italy’s IMQ And Belgium’s SGS Named 15th and 16th IVDR Notified Bodies

 
• By Amanda Maxwell

Ireland’s NSAI reinstated under IVD Regulation designation list

Trump’s Preliminary 2026 HHS Budget Plan Protects US FDA User Fee Collection

 
• By Cathy Kelly

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.

More from Policy & Regulation

‘The FDA Will Be Looking For Avenues To Regulate Laboratory Developed Tests’

 
• By Natasha Barrow

The FDA's final LDT ruling was struck down in federal court last month. For now, diagnostic companies can commercialize under CLIA regulations or apply for FDA approval. McDermott and Tribun Health have shared insights on the risks, pros and cons of both regulatory routes.

Ireland’s Medtech Keeps Calm While Trump Covets Its Healthcare Industry

 
• By Amanda Maxwell

The Republic of Ireland’s record in life sciences is impressive. Decades of investment, education and training have been major winners for the country’s successful economy. But its success is drawing unwanted attention from the US. Trump wants “to have that.”

Keep An Eye On Landmark Global Pandemic Treaty, Experts Advise

 
• By Neena Brizmohun

Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.